

Current Concepts In Anesthesia, Pain Management, And Critical Care Using Ketamine

MUKESH KUMAR , Mrs. CHANDA RAY , Mrs. SANDHYA SHARMA

Department of Pharmaceutics, Innovative College of Pharmacy, Knowledge Park II, Greater Noida, Uttar Pradesh, 201308.

Abstract

When treating unipolar major depressive disorder (MDD), medications that target monoaminergic systems do not act immediately and have significant limits in terms of their efficacy. Antidepressants having major pharmacological targets other than the monoamine system may have the potential to have a more rapid onset of action and provide improved clinical benefit. There has been some research done looking at the glutamate system as a possible target for the creation of antidepressants. This article will review the most recent findings from research conducted on the subject of rapid-onset antidepressant properties exhibited by the anaesthetic drug ketamine. Ketamine has been proven to have these features. K-ketamine, an isomer of the substance, is examined in terms of its pharmacology and how it has been used to treat chronic and refractory pain, a disease that is typically connected with depression. Specifically, this topic will focus on how K-ketamine has been used to treat patients in the past. In the first wave of clinical trials, researchers showed that a single dose of intravenous ketamine (0.5 mg/kg) was both safe and effective in treating patients who suffered from treatment-resistant depression (TRD). Studies that are more recent are looking at the neurological basis for ketamine's alleged antidepressant benefits, as well as discovering ways to prevent relapse once the symptoms of depression have passed. In addition to more traditional methods of assessing depression, researchers are currently investigating the effects that ketamine has on a person's neurocognition.

Keywords: Anti depression, Ketamine, Medication, Neurotransmitter.

Introduction

Ketamine has been utilised in several medical contexts ever since its discovery in the 1970s. It is a one-of-a-kind intravenous (IV) anaesthetic that, in addition to causing sleepiness, catalepsy, somatic analgesia, and bronchodilation, activates the sympathetic nervous system.[1] Ketamine's startling new-drug reactions, its reputation as a "vet medicine," and its burgeoning popularity as a chemical that can lead to addiction are all reasons why anesthesiologists today are less inclined to use it as a treatment option. Ketamine has been a fan favourite for a very long time for several reasons, including the recently revealed medicinal benefits of the substance as well as its peculiar properties.[2][3] It is still utilised in a wide variety of clinical settings even in the present day. The majority of anesthesiologists now receive

minimal or even zero training on the use of ketamine. [4] They are completely unaware of the extent to which ketamine is utilised in the medical field. In light of this, an exhaustive search was conducted in the online databases of PubMed and Cochrane.[5][6] The information needed came from looking through a number of different anaesthetic books and articles. Based on the material presented here, this review paper investigates how ketamine is now being utilised in fields such as anaesthesia, pain treatment, and critical care.[7]

Pharmacology of Ketamine


The N-methyl-d-aspartate (NMDA) receptor for glutamate contains a site called phencyclidine, which acts as a non-competitive antagonist for ketamine. However, the effects of this compound are moderated in part by interactions with a large number of other receptors.[8][9] It is a local anaesthetic that has a brief duration of action and can be given intravenously, intramuscularly, orally, or even through the nose. It has found widespread use among emergency room physicians. It is feasible to use ketamine as a substitute for a number of other anaesthetics without triggering any adverse effects in the patient.[10][11]

Ketamine was utilised as a general anaesthetic as early as the 1960s; however, it is no longer extensively employed today due to the psychological side effects, including delirium and strange dreaming in approximately 12 percent of patients. Ketamine is no longer widely used as a general anaesthetic. Ketamine, on the other hand, has been used for the treatment of acute pain, as well as during surgery and for chronic pain, with subanaesthetic levels of ketamine. Racemic ketamine and chiral ketamine (also written as S+ and R) are the two forms that this substance can take. When it comes to alleviating pain, this substance is two times as effective as racemic ketamine and four times as effective as R-ketamine. As a consequence of this, patients may benefit from taking low doses of S-ketamine since it helps them avoid unpleasant side effects while also providing effective pain relief.[12][13]

S-ketamine administration in intensive care units has been the subject of research regarding both the pharmacology and the adverse effects of ketamine.

Ketamine has the ability to relax the smooth muscles of the airways in children who suffer from asthma, which gives it the potential to be an useful induction medication. In the event that endotracheal intubation is required, it has been suggested that 1–2 mg/kg of lidocaine should be given intravenously before to the intubation procedure; however, the use of a laryngeal mask airway may be more suitable in this scenario. When administered jointly, ketamine and midazolam infusion promotes analgesia, prevents and alleviates bronchospasm, and avoids bronchospasm.[14][15]

Mechanism of Action



An anaesthetic that is dissociative and does not contain barbiturates, ketamine hydrochloride. Deep anaesthesia and relief from pain are two of the effects that can be elicited by this powerful and rapidly acting cyclohexanone derivative.[16] Its chemical name is o-chlorophenyl-2-methylcyclohexanone hydrochloride, and its structural formula is CHCINO. o-chlorophenyl-2-methylcyclohexanone hydrochloride. [17] Ketamine is an antagonist for both glutamate and NMDA receptors, and these two types of receptors do not compete with one another. This medication is effective in inhibiting HCN1 receptors.[18] Opiate mu-receptors have a distinctive dissociation effect and partial agonism, which enables a steady state of sleepiness and patient comfort even throughout the most excruciating of medical procedures. The prolonged pain-relieving and antidepressant effects of ketamine may be linked to the hyper-glutamatergic state that is generated by the use of ketamine. [19][20][21] Secondary structural synaptic connections may play a role in the maintenance of these effects. The N-methyl-D-

aspartate (NMDA) receptor is thought to play a significant function in the pathophysiology of clinical depression. Ketamine's NMDA antagonistic activity is a powerful tool for providing speedy relief from depressive symptoms and thoughts of self-harm. Ketamine is thought to cause an increase in glutamate levels as well as synaptogenesis, which can lead to an increase in brain-derived neurotrophic factor levels (BDNF).[22][23][24] Ketamine has the potential to have an effect on the sigma receptors. Central sensitization, the wind-up phenomenon (which can be defined as the production of ongoing, worsening, or chronic pain), and pain memory are all assumed to have a part in its effectiveness. It would appear that these systems have a considerable function in both sedation and analgesia, with both a positive and a negative influence on the process. Ketamine has the ability to reverse the effects of opioid tolerance. The hepatic metabolism of this substance involves a number of processes, including N-dealkylation, hydroxylation, conjugation, and dehydration.[25][26] The half-life of ketamine begins around 45 minutes after the last dose is taken. Ketamine has a tendency to keep both the pharyngeal and laryngeal reflexes intact, which enables the patient to sustain spontaneous respiration. The tone of the skeletal muscles is maintained or somewhat improved, and the cardiovascular and respiratory systems are both stimulated.[27][28][29][30] When a patient has not been "prepped" for an emergency procedure in advance, short-term procedures in the emergency department benefit immensely from these traits. This is especially true when the patient is being treated for a medical emergency. This is truer than ever before. There is no basis for the expectation that the pharyngeal and laryngeal reflexes will "protect" the airway because it is not guaranteed that their maintenance will be maintained. In addition, there is a possibility of a brief period of moderate respiratory depression if the medication is administered too rapidly or in an excessively high dose. As a consequence of this, the physician needs to be ready to intubate a patient in the event of an emergency.[30][31]

Historical uses of Ketamine

It was developed in 1962 as an alternative to phencyclidine that would produce fewer hallucinations while also acting more quickly (Ket). 1964 was the year that marked the first time that it was made available to the public at large. Patients have a difficult time tolerating Ket because of the hallucinations it generates, in addition to the seizures and other adverse effects that it produces. The use of ket has dramatically decreased as a result of the discovery and development of novel volatile and injectable anaesthetic agents that have favourable emergence and side effect profiles. In the 1990s, the ultrashort-acting opioid known as remifentanyl was created. This made it possible for huge dosages of opioid to be administered in order to reduce the stress associated with exceedingly invasive procedures. If excessive amounts of an opioid are taken, there is a possibility that the patient will have adverse effects such as hyperalgesia and acute tolerance. Because of its analgesic and antihyperalgesic properties, the clinical application of modest doses of ket has been reexamined. Analgesia, anti-shock, anti-inflammatory effects, anti-tumor effects, neuroprotection, and bronchodilation and bronchodilation are some of the reported benefits of cannabis use. At addition, a recent study discovered that this particular anaesthetic, when taken in a low dose, has anti-depressant properties. Ket has a diverse set of interests outside of the medical and surgical professions, in addition to his work in the field of anaesthesia and the operating room.[32][33]

Current uses

As ketamine has been around for over 50 years, it's now being used to treat a variety of conditions, including chronic pain management, anxiety reduction, and inflammation reduction, among others.

For Acute pain management:

Ketamine has been put to use in the medical field as an anaesthetic for more than half a century. At high dosages, it produces amnestic and dissociative anaesthetic effects; nevertheless, at lower concentrations, it possesses analgesic and opioid-sparing qualities. [Citation needed] [Citation needed] Because of its ability to maintain hemodynamic stability and respiratory function, ketamine is an ideal choice for procedural sedation and the facilitation of brief, unpleasant procedures. Ketamine is also a great choice for the facilitation of brief, painful procedures. In spite of the fact that studies indicates that sub-dissociative doses of this analgesic are safe and effective, the emergency department almost never uses it to treat severe pain. Patients who may benefit from the administration of ketamine in a setting of acute pain can now be identified using new guidelines that were issued in July 2018 by the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. These organisations are all involved in the medical field of pain medicine.[34]

For chronic pain management

In the early stages of ketamine's application as an analgesic, intravenous infusion was the method of choice for both avoiding the drug's metabolism in the body's first pass and assuring accurate dosing. As a consequence of this, the medical staff was able to monitor for negative side effects and keep track of the treatment's efficacy during the infusions, which typically took place in hospital settings.[32]

In a meta-analysis that included 211 people who participated in seven separate investigations, an intravenous ketamine infusion was found to have a significant analgesic benefit in both neuropathic and non-neuropathic pain syndromes when compared to a placebo. This comparison was made using data from the studies. It took these patients an average of five hours to reach a ketamine dose of 0.35 mg/kg, which is considered therapeutically effective. In each of the seven experiments, the most significant reduction in pain intensity was observed between 48 hours and two weeks after the infusion. After receiving the injection, there was a significant decrease in the level of pain that patients experienced for up to eight weeks. The effectiveness of ketamine did not differ significantly across the many kinds of pain or the various subcategories of the disorders that cause those kinds of pain. The studies did not find any difference in the medication's efficacy when it was used either as a standalone treatment or as an adjuvant therapy. In each of the seven investigations, the maximum analgesic effect was shown anywhere between 48 hours and two weeks after treatment began.[34][35]

To summarise, it would appear that ketamine could be an effective treatment choice for a wide variety of chronic pain syndromes, including both neuropathic and non-neuropathic forms of the condition. [37] Patients can obtain this treatment outside of the hospital with only as many visits to pain management as are necessary because of the long-lasting analgesic benefits of ketamine. According to the results of

clinical trials, ketamine could be used as a third-line treatment for the pain caused by cancer. 12 cancer patients with intractable pain were given ketamine infusions at a rate of 1.5 mg/kg/day and saw a reduction of 50 percent in their total daily morphine use after being returned home with ketamine/morphine pain pumps. Ketamine infusions were administered after the patients were given pain pumps that contained ketamine and morphine. Only the trial dose given at the beginning caused any adverse effects.[38] [39]

Clinical Studies Brain disorder

Single dose of ketamine

It is currently recommended that analgesia be used as part of a multimodal treatment plan for acute pain. By using multiple analgesics to simultaneously target various pain pathways, it is possible to improve analgesia while simultaneously reducing the amount of opioids used.

Researchers have revived their interest in the anaesthetic ketamine, which was popular in the 1970s. [40]This interest comes as part of a multimodal strategy for treating acute pain. Because it inhibits the activity of NMDA receptors, which play a role in the conduction of inflammatory and nociceptive pain, ketamine is classified as an analgesic. Because of its properties, the K-analgesic ketamine has been the subject of a number of clinical studies that investigate its potential to treat a variety of painful conditions, such as cancer, neuropathy, refractory chronic pain, and acute pain. Others, on the other hand, have refrained from utilising the medicine in the perioperative setting due to the perception that it is associated with the production of unpleasant side effects. At the present time, there is a large amount of variety in the method that is used to give ketamine in the context of the treatment of acute pain. In point of fact, ketamine has been utilised in a range of settings, such as through intravenous (IV), epidural, and wound infusions. It has also been administered in a broad variety of doses, the most typical of which being a single dose bolus of 1 mg/kg, followed by 48 hours of continuous IV infusions of 0.18 mg/kg/h.[41]

Repeat dose of ketamine

A single subanesthetic (intravenous) dose of ketamine administered intravenously (IV) may offer fast but transitory antidepressant effects in people who have depression that is resistant to treatment (TRD). T[45][44] en patients with symptomatic TRD who were not taking any medications and who had previously shown a significant antidepressant response to one dose of IV ketamine in this trial were given an open-label, six-infusion IV treatment of ketamine. The treatment was given under an open label. When administered in low dosages, ketamine produced only a handful of reactions that could be considered positively psychotic. Three of the patients reported experiencing significant dissociative symptoms, however these effects were quite temporary. [42][43]Side effects were minimal during the course of each and every ketamine infusion. Following the first and sixth administrations of the drug, the response criteria were met by nine different people. Following the sixth administration, patients' MADRS scores dropped by an average of 85% (standard deviation) (12 percent). Following the sixth injection of ketamine during the post-ketamine phase, an average of 19 days later, eight out of nine

patients experienced a relapse (range 6 days-45 days). One patient did not take any antidepressant medication for more than three months and only exhibited minor signs of depression during that time.[46]

Impact of suicidal ideation

The prevention of suicide is one of the most pressing concerns that health care professionals have to address. [47][48] The clinical assessment and subsequent reaction are extremely important when considered in the context of suicidality. Keep in mind that taking your own life is a permanent solution looking for a temporary problem.[49] This article provides important statistics and risk factors, identifies the major questions to ask a potentially suicidal individual, details the actual steps to ensure the patient's safety, and concludes with steps that should be addressed with family and friends in the case of a completed suicide in order for clinicians to recognise patients who require special intervention. If a person has suicidal thoughts, the next thing that makes sense to ask is whether or not they have made any specific plans to end their own life. If they do, then it is important to take action immediately. A higher level of risk is indicated whenever there is a comprehensive plan in place.[50] Although nebulous threats, such as a threat to commit suicide in the future, are cause for concern, responses suggesting that the individual has purchased a gun, additional ammunition, wrote a will, and plans to use the gun are more dangerous than the gun itself are more concerning. [50][51]Concerning the proposition, questions need to be raised. If the person foresees their own death as being caused by a firearm, it is important to determine whether or not they are in possession of a weapon or have access to one. Investigate to discover if the person is entertaining any thoughts of ending their own life. Both having suicidal thoughts and acting on such ideas are connected. This might be a challenging question for some physicians who are just starting out. They don't ask because they're afraid it would make them feel uncomfortable or cause them to have suicidal thoughts. It is true that patients appreciate the inquiry since they view it as a display of concern on the part of the doctor. If the answer to the question is yes, then you need to investigate the matter further more.[52]

Conclusion

In order to better understand the early reports of ketamine for treatment-resistant unipolar major depression, the goal of this review was to contextualise those experiences. Because of its lengthy history of usage as an anaesthetic and analgesic medicine, there is still a great deal that we do not know about the pharmacological profile of the medication when it comes to treating depression. We do not know which specific pathways are important for the early and sustained improvements observed in some patients during clinical trials while ketamine attenuates the function of NMDA receptors. These pathways include modulation of glutamate release, effects on glutamate receptor activation, extracellular clearance, and metabolism.

In spite of the fact that clinical trials of ketamine for major depressive disorder are just getting off the ground, it is essential to keep in mind that the overall efficacy of ketamine in clinical settings has not been fully examined. Early ketamine research generated a lot of excitement; however, there are a number of factors that call into question the reliability of the saline-controlled, within-subjects crossover

design, raise concerns about how long the antidepressant effects of ketamine last, and cast doubt on whether or not it is safe to use in this population. By the year 2020, there will not have been any randomised, well-controlled trials of repeated-dose ketamine for MDD that have been published in the literature that has been peer-reviewed.

References:

1. Kumar, R., Saha, P., Kumar, Y., Sahana, S., Dubey, A., & Prakash, O. (2020). A Review on Diabetes Mellitus: Type1 & Type2. *World Journal of Pharmacy and Pharmaceutical Sciences*, 9(10), 838-850.
2. KUMAR, A. (2019). The Scenario of Pharmaceuticals and Development of Microwave Assisted Extraction Techniques.
3. Hui DS, I Azhar E, Madani TA, et al.. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis*. 2020;91:264–266.
4. Wiersinga WJ, Rhodes A, Cheng AC, et al.. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *JAMA*. 2020;324:782–793.
5. KUMAR, R., SAHA, P., SARKAR, S., RAWAT, N., & PRAKASH, A. (2021). A REVIEW ON NOVEL DRUG DELIVERY SYSTEM. *IJRAR-International Journal of Research and Analytical Reviews (IJRAR)*, 8(1), 183-199.
6. Saha, P., Nyarko, R. O., Lokare, P., Kahwa, I., Boateng, P. O., & Asum, C. (2022). Effect of Covid-19 in Management of Lung Cancer Disease: A Review. *Asian Journal of Pharmaceutical Research and Development*, 10(3), 58-64.
7. Kumar, R., Saha, P., Pathak, P., Mukherjee, R., Kumar, A., & Arya, R. K. EVOLUTION OF TOLBUTAMIDE IN THE TREATMENT OF DIABETES MELLITUS. *Jour. of Med. P'ceutical & Alli. Sci*, 9.
8. Kumar, R., Jain, A., Tripathi, A. K., & Tyagi, S. (2021, January). Covid-19 outbreak: An epidemic analysis using time series prediction model. In 2021 11th international conference on cloud computing, data science & engineering (Confluence) (pp. 1090-1094). IEEE.
9. Nyarko, R. O., Saha, P., Kumar, R., Kahwa, I., Boateng, E. A., Boateng, P. O., ... & Bertram, A. (2021). Role of Cytokines and Vaccines in Break through COVID 19 Infections. *Journal of Pharmaceutical Research International*, 33, 2544-2549.
10. PURABISAHA, R. K., RAWAT, S. S. N., & PRAKASH, A. (2021). A REVIEW ON NOVEL DRUG DELIVERY SYSTEM.

11. Nyarko, R. O., Boateng, E., Kahwa, I., Boateng, P. O., & Asare, B. (2020). The impact on public health and economy using lockdown as a tool against COVID-19 pandemic in Africa: a perspective. *J Epidemiol Public Health Rev*, 5(3).
12. Raj, A., Tyagi, S., Kumar, R., Dubey, A., & Hourasia, A. C. (2021). Effect of isoproterenol and thyroxine in herbal drug used as cardiac hypertrophy. *Journal of Cardiovascular Disease Research*, 204-217.
13. Daharia, A., Jaiswal, V. K., Royal, K. P., Sharma, H., Joginath, A. K., Kumar, R., & Saha, P. (2022). A Comparative review on ginger and garlic with their pharmacological Action. *Asian Journal of Pharmaceutical Research and Development*, 10(3), 65-69.
14. Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, Viscusi ER, Narouze S, Davis FN, Ritchie EC, Lubenow TR, Hooten WM. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. *Reg Anesth Pain Med*. 2018 Jul;43(5):521-546.
15. Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, Bhatia A, Davis FN, Hooten WM, Cohen SP. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. *Reg Anesth Pain Med*. 2018 Jul;43(5):456-466.
16. Bokor G, Anderson PD. Ketamine: an update on its abuse. *J Pharm Pract*. 2014 Dec;27(6):582-6.
17. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, Li XY, Aghajanian G, Duman RS. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. *Biol Psychiatry*. 2011 Apr 15;69(8):754-61
18. Li JH, Vicknasingam B, Cheung YW, Zhou W, Nurhidayat AW, Jarlais DC, Schottenfeld R. To use or not to use: an update on licit and illicit ketamine use. *Subst Abuse Rehabil*. 2011;2:11-20
19. Rabiner EA. Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen? *J Psychopharmacol*. 2007 May;21(3):253-8
20. Pham TH, Gardier AM. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. *Pharmacol Ther*. 2019 Jul;199:58-90
21. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. *J Pharmacol Exp Ther*. 1992 Mar;260(3):1209-13.
22. Ben-Shlomo I, Rosenbaum A, Hadash O, Katz Y. Intravenous midazolam significantly enhances the lethal effect of thiopental but not that of ketamine in mice. *Pharmacol Res*. 2001 Dec;44(6):509-12.
23. Hansen G, Jensen SB, Chandresh L, Hilden T. The psychotropic effect of ketamine. *J Psychoactive Drugs*. 1988 Oct-Dec;20(4):419-25.
24. Deer TR, Pope JE, Hayek SM, Lamer TJ, Veizi IE, Erdek M, Wallace MS, Grider JS, Levy RM, Prager J, Rosen SM, Saulino M, Yaksh TL, De Andrés JA, Abejon Gonzalez D, Vesper J, Schu S, Simpson B, Mekhail N. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug

- Delivery: Guidance for Improving Safety and Mitigating Risks. *Neuromodulation*. 2017 Feb;20(2):155-176.
25. Sarton E, Teppema LJ, Olievier C, Nieuwenhuijs D, Matthes HW, Kieffer BL, Dahan A. The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. *Anesth Analg*. 2001 Dec;93(6):1495-500, table of contents.
26. Demaria S, Weinkauff JL. Cocaine and the club drugs. *Int Anesthesiol Clin*. 2011 Winter;49(1):79-101.
27. Nyarko, R. O., Kumar, R., Sharma, S., Chourasia, A., Roy, A., & Saha, P. (2022). ANTIBACTERIAL ACTIVITY OF HERBAL PLANT-TINOSPORA CORDIFOLIA AND CATHARANTHUS ROSEUS.
28. Singh, M. K., Kumar, A., Kumar, R., Kumar, P. S., Selvakumar, P., & Chourasia, A. (2022). Effects of Repeated Deep Frying on Refractive Index and Peroxide Value of Selected Vegetable Oils. *International Journal for Research in Applied Sciences and Biotechnology*, 9(3), 28-31.
29. Kumar, R., & Dubey, A. PHYTOCHEMICAL INVESTIGATION AND HEPTOPROTECTIVE EVALUTION ACACIA RUBICA EXTRACT ISONIZED AND PARACETAMOL INDUSED ANIMAL TOXICITY. *Turkish Journal of Physiotherapy and Rehabilitation*, 32(3).
30. Nyarko, R. O., Prakash, A., Kumar, N., Saha, P., & Kumar, R. (2021). Tuberculosis a globalized disease. *Asian Journal of Pharmaceutical Research and Development*, 9(1), 198-201.
31. Nyarko, R. O., Boateng, E., Kahwa, I., & Boateng, P. O. (2020). A comparison analysis on remdesivir, favipiravir, hydroxychloroquine, chloroquine and azithromycin in the treatment of corona virus disease 2019 (COVID-19)-A Review. *World J. Pharm. Pharm. Sci*, 9, 121-133.
32. Sahana, S., Kumar, R., Nag, S., Paul, R., Chatterjee, I., & Guha, N. (2020). A REVIEW ON ALZHEIMER DISEASE AND FUTURE PROSPECTS.
33. Sahana, S. (2020). Roshan kumar, Sourav nag, Reshmi paul, Nilayan guha, Indranil Chatterjee. A Review on Alzheimer disease and future prospects. *World Journal of Pharmacy and Pharmaceutical science*, 9(9), 1276-1285.
34. Saha, P., Kumar, R., Nyarko, R. O., Kahwa, I., & Owusu, P. (2021). HERBAL SECONDARY METABOLITE FOR GASTRO-PROTECTIVE ULCER ACTIVITY WITH API STRUCTURES.
35. Saha, P., Kumar, R., Nyarko, R. O., Kahwa, I., & Owusu, P. (2021). HERBAL SECONDARY METABOLITE FOR GASTRO-PROTECTIVE ULCER ACTIVITY WITH API STRUCTURES.
36. Dubey, A., Yadav, P., Verma, P., & Kumar, R. (2022). Investigation of Proapoptotic Potential of Ipomoea carnea Leaf Extract on Breast Cancer Cell Line. *Journal of Drug Delivery and Therapeutics*, 12(1), 51-55.

37. Bind, A., Das, S., Singh, V. D., Kumar, R., Chourasia, A., & Saha, P. Natural Bioactives For The Potential Management Of Gastric Ulceration. *Turkish Journal of Physiotherapy and Rehabilitation*, 32(3).
38. Kumar, R., Saha, P., Lokare, P., Datta, K., Selvakumar, P., & Chourasia, A. (2022). A Systemic Review of *Ocimum sanctum* (Tulsi): Morphological Characteristics, Phytoconstituents and Therapeutic Applications. *International Journal for Research in Applied Sciences and Biotechnology*, 9(2), 221-226.
39. Sahana, S. (2020). Purabi saha, Roshan kumar, Pradipta das, Indranil Chatterjee, Prasit Roy, Sk Abdur Rahamat. A Review of the 2019 Corona virus (COVID-19) *World Journal of Pharmacy and Pharmaceutical science*, 9(9), 2367-2381.
40. Kumar, R., Saha, P., Lokare, P., Datta, K., Selvakumar, P., & Chourasia, A. (2022). A Systemic Review of *Ocimum sanctum* (Tulsi): Morphological Characteristics, Phytoconstituents and Therapeutic Applications. *International Journal for Research in Applied Sciences and Biotechnology*, 9(2), 221-226.
41. Roshan, K. (2020). Priya damwani, Shivam kumar, Adarsh suman, Suthar Usha. An overview on health benefits and risk factor associated with coffee. *International Journal Research and Analytical Review*, 7(2), 237-249.
42. Umama, Y., Venkatajah, G., Shourabh, R., Kumar, R., Verma, A., Kumar, A., & Gayoor, M. K. (2019). Topic-The scenario of pharmaceuticals and development of microwave assisted extraction technique. *World J Pharm Pharm Sci*, 8(7), 1260-1271.
43. Awuchi, C. G., Amagwula, I. O., Priya, P., Kumar, R., Yezdani, U., & Khan, M. G. (2020). Aflatoxins in foods and feeds: A review on health implications, detection, and control. *Bull. Environ. Pharmacol. Life Sci*, 9, 149-155.
44. SHAFQAT ZAIDI, R. K. MEHRA, Dr. SACHIN TYAGI, ROSHAN KUMAR ANUBHAV DUBEY.(2021). Effect of Kalahari Cactus Extract on Appetite, Body Weight And Lipid Profile In Cafeteria Diet Induced Obesity In Experimental Animal. *Annals of the Romanian Society for Cell Biology*, 25(6), 13976-13987.
45. Roshan Kumar, & Purabi Saha. (2022). A Review on Artificial Intelligence and Machine Learning to Improve Cancer Management and Drug Discovery. *International Journal for Research in Applied Sciences and Biotechnology*, 9(3), 149–156. <https://doi.org/10.31033/ijrasb.9.3.26>
46. Li L, Vlisides PE. Ketamine: 50 Years of Modulating the Mind. *Front Hum Neurosci*. 2016;10:612
47. Corssen G, Domino EF. Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. *Anesth Analg*. 1966 Jan-Feb;45(1):29-40.

48. Liao Y, Tang YL, Hao W. Ketamine and international regulations. *Am J Drug Alcohol Abuse*. 2017 Sep;43(5):495-504.
49. Cartwright PD, Pingel SM. Midazolam and diazepam in ketamine anaesthesia. *Anaesthesia*. 1984 May;39(5):439-42.
50. Andrade C. Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. *J Clin Psychiatry*. 2017 Apr;78(4):e415-e419.
51. Tobias JD, Leder M. Procedural sedation: A review of sedative agents, monitoring, and management of complications. *Saudi J Anaesth*. 2011 Oct;5(4):395-410.
52. Chyka PA, Seger D. Position statement: single-dose activated charcoal. *American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol*. 1997;35(7):721-41.